Health regulator says serious side-effects possibly caused by insulin in counterfeit versions of Novo Nordisk’s Ozempic
Several people have been admitted to hospital in Austria after using suspected fake versions of Novo Nordisk’s diabetes drug Ozempic, the country’s health safety body has said, the first report of harm to users as a European hunt for counterfeiters widened.
The patients were reported to have suffered hypoglycaemia and seizures, serious side-effects that indicate that the product contained insulin instead of Ozempic’s active ingredient semaglutide, the health safety regulator Bundesamt für Sicherheit im Gesundheitswesen (BASG) said on Monday.
About Author
More Stories
China accuses UK politicians of ‘arrogance’ in British Steel row
In the red: global wine sales fall to lowest levels since 1961
ECB cuts rates for third time this year as Europe braces for Trump tariffs